# TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19

> **NCT04573855** · PHASE1,PHASE2 · UNKNOWN · sponsor: **D'Or Institute for Research and Education** · enrollment: 41 (estimated)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Anti-SARS-CoV-2 immunoglobulin

## Key facts

- **NCT ID:** NCT04573855
- **Lead sponsor:** D'Or Institute for Research and Education
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-03-31
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04573855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04573855, "TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04573855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*